50343-02-7

Usage

Uses

Used in Pharmaceutical Industry:
3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its structural features make it a key component in the creation of molecules with potential therapeutic properties.
Used in Dye Industry:
In the dye industry, 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE is utilized as an intermediate for the preparation of various dyes, leveraging its chemical properties to produce a range of colorants for different applications.
Used in Organic Synthesis:
3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE is used as a versatile building block in organic synthesis for its capacity to form the basis of a wide array of organic compounds, contributing to the diversity of chemical products.
Used in Material Development:
3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE is used in the development of new materials, where its unique characteristics can enhance or provide novel properties to the materials being researched and developed.
Used as a Research Reagent:
In chemical research, 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE serves as a reagent, facilitating various experimental procedures and contributing to the advancement of scientific knowledge.
Used in Medicinal Chemistry and Drug Discovery:
3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE is used in the field of medicinal chemistry and drug discovery for its potential to be part of the molecular structure of new therapeutic agents, highlighting its importance in the search for innovative treatments.

InChI:InChI=1/C8H7BrO3/c1-12-6-2-5(4-10)8(11)7(9)3-6/h2-4,11H,1H3

Upstream product

• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 150-76-5 4-methoxy-phenol 
• 5446-02-6 4-methoxymethylsalicylate 
• 2612-02-4 5-methoxysalicylic acid 
• 7726-95-6 bromine 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 

Downstream Products

• 68216-65-9 3-bromo-2,5-dimethoxybenzaldehyde 
• 1000414-99-2 N-(3-bromo-5-methoxysalicylidene)-3-[bis(5-methyl-2-furyl)methyl]aniline 
• 885025-15-0 (E)-3-(3-bromo-2-hydroxy-5-methoxy-phenyl)-acryIic acid ethyl ester 
• 198757-93-6 (R)-N-(3-benzenesulfonylmethyl-2,5-dimethoxyphenyl)-4-(tert-butyldimethylsilyloxy)-3-methoxybutyramide 
• 669065-39-8 1-bromo-3-bromomethyl-2,5-dimethoxymethylbenzene 
• 196302-51-9 (3-Bromo-2,5-dimethoxy-phenyl)-methanol 
• 669065-37-6 1-bromo-3-benzenesulfonylmethyl-2,5-dimethoxymethylbenzene 
• 669065-35-4 [1(3Z,5R,6S,7S,9E),3R,4E]-3-methoxy-hepta-4,6-dienoic acid {3-[7-(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-dodeca-3,9,11-trienyl]-2,5-dimethoxy-phenyl}-amide 
• 669065-45-6 [1(3Z,5R,6S,7S),3R]-N-{3-[7-(tert-butyl-dimethylsilyloxy)-9-oxo-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-3-methoxy-4-oxo-N-(2,2,2-trichloroethoxymethyl)-butyramide 
• 669065-55-8 [1(3Z,5R,6S,7S),3R]-N-{3-[7-(tert-butyl-dimethylsilyloxy)-9-hydroxy-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-hydroxy-3-methoxy-N-(2,2,2-trichloroethoxymethyl)-butyramide 
• 669065-44-5 [1(3Z,5R,6S,7S),3R]-N-{3-[7,9-bis(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-(tert-butyldimethylsilyloxy)-3-methoxy-butyramide 
• 669065-54-7 [1(3Z,5R,6S,7S),3R]-N-{3-[7,9-bis(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-(tert-butyldimethylsilyloxy)-3-methoxy-N-(2,2,2-trichloroethoxymethyl)-butyramide 
• 669065-53-6 [1(1RS,3Z,5R,6S,7S),3R]-N-{3-[1-benzenesulfonyl-7,9-bis(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-(tert-butyldimethylsilyloxy)-3-methoxy-butyramide 

Relevant academic research and scientific papers

NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES

Disclosed are compounds having formula (I) or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6, and Effector are each as defined in the specification; compositions thereof; uses thereof; and methods of use thereof.

SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE

Disclosed are compounds having formula (I): or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6 are each as defined in the specification; compositions thereof; uses thereof; and methods of use thereof.

LABELLED COUMARIN DERIVATIVES

The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive compounds. The radioactive compounds of the invention can find use for in vivo imaging applications.

Synthesis and Evaluation of Novel 7- and 8-Aminophenoxazinones for the Detection of β-Alanine Aminopeptidase Activity and the Reliable Identification of Pseudomonas aeruginosa in Clinical Samples

A series of novel 8-aminophenoxazin-3-one and 7-aminophenoxazin-3-one chromogens and their corresponding β-alanine derivatives were synthesized and evaluated for their ability to detect β-alanyl aminopeptidase activity in bacteria known to hydrolyze β-ala

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells

Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. (Figure Presented).

2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774

The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted;R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocycl

PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION

The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

Tetracyclic compounds as estrogen ligands

This invention provides estrogen receptor modulators having the structure: wherein R1, R2, R3, R4, Q, n, R8, R9, R10, and R11 have been defined in the specification; o

Ligand tuning in the chromium-salen-mediated asymmetric epoxidation of alkenes

A series of Cr(salen) complexes have been synthesised from 5-substituted-3-bromosalicylaldehydes and trans-1,2-cyclohexanediamine. These have been used to probe the Cr(salen)-mediated asymmetric epoxidation of alkenes. No simple correlation was found between the electronic character of the salen-substituents and the enantioselectivity - multiple oxidation pathways are proposed as a possible explanation. Enantioselectivities of up to 90% have been achieved using a novel, synthetically accessible Cr(salen) complex.

A Convergent Synthesis of the Macrocyclic Core of Cytotrienins: Application of RCM for Macrocyclization

(Equation presented) The asymmetric synthesis of the fully elaborated macrocyclic core of cytotrienins A-D, potent apoptosis-inducing agents, is described. Synthetic highlights include the construction of the aniline bond using a copper-mediated amidation and the use of a ring-closing metathesis (RCM) reaction to efficiently install the (E,E,E)-triene and simultaneously construct the macrocyclic lactam.